Syrjänen Stina, Rautava Jaana
Department of Oral Pathology, Faculty of Medicine, Turku University Hospital, Institute of Dentistry, University of Turku, Lemminkäisenkatu 2, 20520, Turku, Finland.
Recent Results Cancer Res. 2017;206:257-267. doi: 10.1007/978-3-319-43580-0_21.
HPV-associated head and neck squamous cell carcinoma (HNSCC), more specifically the incidence of oropharyngeal cancer, is dramatically increasing in industrialized countries. According to what has been learned from anogenital vaccination programs, there are reasons to believe that current human papillomavirus (HPV) vaccinations may be potentially effective also against HNSCC. However, before specific results on HNSCC are available, one must keep in mind that carcinogenesis in the head and neck region may differ from that of the anogenital tract. Furthermore, the current evidence supports the view that HPV infection is much more complex than simply a sexually transmitted disease. HPV is present in the semen, placenta and in the newborns, and these infections of the newborns create cell-mediated immunity (CMI) against HPV, including the T memory cells. Acquisition of HPV infection in early life will rise new series of questions in the field of HPV vaccination.
人乳头瘤病毒（HPV）相关的头颈部鳞状细胞癌（HNSCC），更具体地说是口咽癌的发病率，在工业化国家正急剧上升。根据从肛门生殖器疫苗接种计划中所了解到的情况，有理由相信目前的人乳头瘤病毒（HPV）疫苗接种可能对HNSCC也有潜在效果。然而，在获得关于HNSCC的具体结果之前，必须牢记头颈部区域的致癌过程可能与肛门生殖器区域不同。此外，目前的证据支持这样一种观点，即HPV感染远比单纯的性传播疾病复杂得多。HPV存在于精液、胎盘和新生儿体内，而新生儿的这些感染会产生针对HPV的细胞介导免疫（CMI），包括T记忆细胞。早年感染HPV会在HPV疫苗接种领域引发一系列新问题。
